comprehensive -WSS

comprehensive

author：knowledge 2025-10-02 22:56:44 - browse：6

Pascal Soriot 2019 — Pascal Soriot has served as CEO of AstraZeneca since 2012. Win McNamee/Getty Images

CAMBRIDGE, England — On a bit of a roll, AstraZeneca on Tuesday laid out ambitious growth goals for the rest of the decade, seeking to build on its momentum in fields like oncology as it said it would nearly double its revenue to $80 billion by 2030.

Hitting such a target would depend on the launch of 20 new medicines and continued growth of its cancer and rare disease therapies, as well as other drugs. It would also require outpacing the targets laid out by AstraZeneca’s large pharma peers.

But at an investor day here at the company’s shiny new Discovery Centre, CEO Pascal Soriot opened his presentation by bringing up the goal set by the company a decade ago — $45 billion in revenue by 2023. The company faced some declines early in that period, but after surging in the past few years, it hit that target, bringing in $45.8 billion last year. Its recent growth has also propelled the company’s share price.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Experts study whether long Covid risk adds up with each reinfection

WSS

Some top drug companies are starting to take action on climate

Novartis develops a rapidly manufactured CAR

Stop Congress from blocking public access to science

The response to Covid

Health insurers' Q3 question: how much care are people getting?

Will an HIV vaccine ever be a reality?

explore

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

How one medical school became remarkably diverse

Study points to new risk in gene therapy death of Terry Horgan

Peter Hotez and the public health issue of online harassment

Sophia Smith scores twice for US in in 3

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

CDC picks Alphabet's Verily for wasterwater surveillance contract

At least 13 dead in Texas as scorching temps continue

Hundreds of thousands march in Israel. Former security chiefs beg Netanyahu to halt legal overhaul

23andMe had bad news about my health. I wish a person had delivered it

Setback for rare diseases as Taysha Gene Therapies pulls back

focus

PrEP can help anyone prevent HIV. Why do so few people take it?

My chronic pain journey would have been easier knowing 5 things % STAT

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

New oral drug delivery patch is modeled after octopus tentacles

Statins reduce cardiovascular risk in people living with HIV

Burning questions about Delta and the next phase of the Covid pandemic

Wikipedia

Wikipedia

focus

Wikipedia